Enlivex Therapeutics Ltd. (ENLV)
NASDAQ: ENLV · Real-Time Price · USD
0.929
+0.088 (10.50%)
Nov 22, 2024, 4:00 PM EST - Market closed
Company Description
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel.
Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis.
The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.
Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Enlivex Therapeutics Ltd.
| Country | Israel |
| Founded | 2005 |
| IPO Date | Dec 12, 1995 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 71 |
| CEO | Oren Hershkovitz |
Contact Details
Address: 14 Einstein Street Ness Ziona, 7403618 Israel | |
| Phone | 972 2 670 8072 |
| Website | enlivex.com |
Stock Details
| Ticker Symbol | ENLV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000919794 |
| CUSIP Number | M4130Y106 |
| ISIN Number | IL0011319527 |
| Employer ID | 95-4102687 |
| SIC Code | 7372 |
Key Executives
| Name | Position |
|---|---|
| Dr. Oren Hershkovitz Ph.D. | Chief Executive Officer |
| Shai Novik M.B.A. | Executive Chairman |
| Shachar Shlosberger CPA | Chief Financial Officer |
| Veronique Amor-Baroukh | Senior Director of Operations |
| Sigal Arad | Director of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 3, 2008 | 15-12G | Securities registration termination |
| Oct 3, 2008 | 8-K | Current Report |
| Oct 2, 2008 | 25-NSE | Filing |
| Sep 25, 2008 | 8-K | Current Report |
| Sep 25, 2008 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Sep 9, 2008 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Sep 9, 2008 | 425 | Filing |
| Sep 5, 2008 | 8-K | Current Report |
| Sep 5, 2008 | 425 | Filing |
| Aug 27, 2008 | 425 | Filing |